MX2010005048A - 4-[4-(2-adamantylcarbamoyl)-5-tert-butyl-pyrazol-1-yl]benzoic acid - 465. - Google Patents

4-[4-(2-adamantylcarbamoyl)-5-tert-butyl-pyrazol-1-yl]benzoic acid - 465.

Info

Publication number
MX2010005048A
MX2010005048A MX2010005048A MX2010005048A MX2010005048A MX 2010005048 A MX2010005048 A MX 2010005048A MX 2010005048 A MX2010005048 A MX 2010005048A MX 2010005048 A MX2010005048 A MX 2010005048A MX 2010005048 A MX2010005048 A MX 2010005048A
Authority
MX
Mexico
Prior art keywords
adamantylcarbamoyl
pyrazol
tert
butyl
benzoic acid
Prior art date
Application number
MX2010005048A
Other languages
Spanish (es)
Inventor
James Stewart Scott
Paul Robert Owen Whittamore
Martin Packer
Andrew Stocker
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/GB2008/000454 external-priority patent/WO2008099145A1/en
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MX2010005048A publication Critical patent/MX2010005048A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

4-[4-(2-Adamantylcarbamoyl)-5-tert-butyl-pyrazol- 1 -yl]benzoic acid and pharmaceutically-acceptable salts thereof and a particular crystalline form of the Agent (Form 1); their use in the inhibition of 11 betaHSD1, processes for making them and pharmaceutical compositions comprising them are also described.
MX2010005048A 2007-11-06 2008-11-05 4-[4-(2-adamantylcarbamoyl)-5-tert-butyl-pyrazol-1-yl]benzoic acid - 465. MX2010005048A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US98573507P 2007-11-06 2007-11-06
PK10808 2008-02-04
PCT/GB2008/000454 WO2008099145A1 (en) 2007-02-12 2008-02-11 Pyrazole derivatives as 11-beta-hsd1 inhibitors
US8230408P 2008-07-21 2008-07-21
PCT/GB2008/051029 WO2009060232A1 (en) 2007-11-06 2008-11-05 4-[4-(2-adamantylcarbamoyl)-5-tert-butyl-pyrazol-1-yl]benzoic acid - 465

Publications (1)

Publication Number Publication Date
MX2010005048A true MX2010005048A (en) 2010-07-28

Family

ID=42759138

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010005048A MX2010005048A (en) 2007-11-06 2008-11-05 4-[4-(2-adamantylcarbamoyl)-5-tert-butyl-pyrazol-1-yl]benzoic acid - 465.

Country Status (17)

Country Link
US (1) US20110060022A1 (en)
EP (1) EP2217232A1 (en)
JP (1) JP2011502978A (en)
KR (1) KR20100095439A (en)
CN (1) CN101909621A (en)
AU (1) AU2008326226B2 (en)
BR (1) BRPI0819177A2 (en)
CA (1) CA2703781A1 (en)
CO (1) CO6270318A2 (en)
CR (1) CR11415A (en)
DO (1) DOP2010000135A (en)
EA (1) EA201000701A1 (en)
EC (1) ECSP10010159A (en)
IL (1) IL205455A0 (en)
MX (1) MX2010005048A (en)
WO (1) WO2009060232A1 (en)
ZA (1) ZA201003031B (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0618885A8 (en) 2005-11-21 2018-06-26 Shionogi & Co heterocyclic compounds having inhibitory activity of 11betahydroxysteroid dehydrogenase type i
TW200827346A (en) 2006-11-03 2008-07-01 Astrazeneca Ab Chemical compounds
TW200836719A (en) 2007-02-12 2008-09-16 Astrazeneca Ab Chemical compounds
ES2535317T3 (en) 2007-05-18 2015-05-08 Shionogi & Co., Ltd. Nitrogen-containing heterocyclic derivative that has 11 beta-hydroxysteroid dehydrogenase inhibitor activity
US7951833B2 (en) * 2008-02-04 2011-05-31 Astrazeneca Ab Crystalline forms of 4-[4-(2-adamantylcarbamoyl)-5-tert-butyl-pyrazol-1-yl]Benzoic acid 471
BRPI0910734A2 (en) * 2008-04-22 2015-09-29 Astrazeneca Ab compound, pharmaceutical composition, and process for preparing a compound or a pharmaceutically acceptable salt thereof.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1492541A1 (en) 2002-04-05 2005-01-05 The University Of Edinburgh Pharmaceutical compositions comprising a 11-beta hydroxysteroid dehydrogenase inhibitor and a diuretic agent
WO2004089470A2 (en) * 2003-04-11 2004-10-21 Novo Nordisk A/S New amide derivatives and pharmaceutical use thereof
EP1889842A4 (en) * 2005-06-08 2009-07-29 Japan Tobacco Inc Heterocyclic compound

Also Published As

Publication number Publication date
AU2008326226B2 (en) 2011-10-20
IL205455A0 (en) 2010-12-30
JP2011502978A (en) 2011-01-27
KR20100095439A (en) 2010-08-30
CA2703781A1 (en) 2009-05-14
ZA201003031B (en) 2011-10-26
AU2008326226A1 (en) 2009-05-14
EA201000701A1 (en) 2010-12-30
CN101909621A (en) 2010-12-08
WO2009060232A1 (en) 2009-05-14
EP2217232A1 (en) 2010-08-18
ECSP10010159A (en) 2010-06-29
US20110060022A1 (en) 2011-03-10
CO6270318A2 (en) 2011-04-20
DOP2010000135A (en) 2010-06-30
CR11415A (en) 2010-08-27
BRPI0819177A2 (en) 2015-05-05

Similar Documents

Publication Publication Date Title
MX2010008583A (en) Novel crystalline forms of 4- [4- (2-adamantylcarbam0yl) -5-tert-butyl-pyrazol-1-yl] benzoic acid.
HK1134087A1 (en) Pyridazine derivatives as 11beta-hydroxysteroid dehydrogenase type 1 inhibitors
NO20070458L (en) Aryl-pyridine derivatives as 11-Beta-HSD1 inhibitors
NO20085121L (en) Benzimidazole derivatives, their preparation mate, their use as FXR agonists and pharmaceutical compositions containing the same
MX2011012017A (en) Azacyclic spiroderivatives as hsl inhibitors.
IN2012DN03337A (en)
MY147994A (en) Azabiphenylaminobenzoic acid derivatives as dhodh inhibitors
DE602006021539D1 (en) Morpholine als 5ht2c-agonisten
NO20084418L (en) Azolopyridin-3-one derivatives as inhibitors of endothelial lipase
NO20091548L (en) Imidazolone and imidazolidinone derivatives as 11B-HSD1 inhibitors of diabetes
MY140514A (en) Triazolopyridine derivatives as inhibitors of lipases and phospholipases
WO2007082808A3 (en) Thiazoles as 11 beta-hsd1 inhibitors
MX2010005048A (en) 4-[4-(2-adamantylcarbamoyl)-5-tert-butyl-pyrazol-1-yl]benzoic acid - 465.
UA90742C2 (en) Pyrazolone derivatives
WO2006000371A3 (en) Pyrimidine derivatives as 11beta-hsd1 inhibitors
MX2010001338A (en) Pyrimidine and pyridine derivatives and their pharmaceutical use and compositions.
UA105057C2 (en) Composition of 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine
MY139522A (en) New alkyl-pyridines as 11-beta inhibitors for diabetes
DK2368887T3 (en) 1, 2, 3-TRIAZOLD DERIVATIVES FOR USE AS STEAROYL-COA DESATURASE INHIBITORS
MX2008016426A (en) Alkyl-pyridazine derivatives as inhibitors of 11 beta hydroxysteroid dehydrogenase type 1(11b-hsd 1).
WO2009068468A3 (en) Pyridine compounds
UA96759C2 (en) 2-ARYLINDOLE DERIVATIVES AS mPGES-I INHIBITORS
MX2009003169A (en) Sulfonamide derivatives.
IN2012DN01232A (en)
WO2008015139A3 (en) Inhibitors of zinc proteases thioaryl substituted and their use

Legal Events

Date Code Title Description
FA Abandonment or withdrawal